Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

The team found that the tirzepatide-treated mice lost about 20 percent of their body weight, mostly from reduced fat mass. In ...

New research reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Experts urge ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular ...

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

Clinical trial data review on weight-loss drugs reveals weight regain patterns post-medication discontinuation, impacting weight management strategies.